Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab

Author:

Sørensen Per Soelberg1,Bertolotto Antonio2,Edan Gilles3,Giovannoni Gavin4,Gold Ralf5,Havrdova Eva6,Kappos Ludwig7,Kieseier Bernd C8,Montalban Xavier9,Olsson Tomas10

Affiliation:

1. Danish Multiple Sclerosis Center, Department of Neurology, Rigshospitalet and Copenhagen University, Denmark.

2. Centro Riferimento Regionale Sclerosi Multipla & Neurobiologica Clinica, Orbassano, Italy

3. Service de Neurologie, CIC-P 0203 INSERM, CHU Rennes, France.

4. Queen Mary University London, Blizard Institute of Cell and Molecular Science, Barts and The London School of Medicine and Dentistry, UK

5. Department of Neurology, St. Josef-Hospital, Ruhr-University Bochum, Germany.

6. Department of Neurology, Charles University in Prague, Czech Republic.

7. Departments of Neurology and Biomedicine, University Hospital, Basel, Switzerland

8. Department of Neurology, Heinrich-Heine University, Düsseldorf, Germany.

9. Unitat de Neuroimmunologia Clínica, Hospital Universitari Vall d’Hebron (HUVH), Barcelona, Spain

10. Center for Molecular Medicine, Karolinska Institute, Stockholm, Sweden, The MS Clinic

Abstract

Natalizumab is a highly effective immunomodulator in the treatment of multiple sclerosis (MS). Treatment with natalizumab has been associated with progressive multifocal leukoencephalopathy (PML), an infection of the central nervous system (CNS) caused by a pathogenic form of the normally benign JC virus (JCV). We searched PubMed and used current data from the natalizumab global safety database to assess risk factors and quantify the risk of PML. Natalizumab treatment duration and prior use of immunosuppressive therapies are established risk factors for development of PML in natalizumab-treated patients. With the development of a reliable and validated assay for detection of antibodies in patients with MS directed against JCV, it is now possible to identify persons who are carriers of JCV. The availability of this assay provides an additional option for risk stratification of PML in patients using or considering natalizumab therapy. Recommendations for clinical management of patients with MS and use of natalizumab are provided based on the presence of these three risk factors. The identification of risk factors that increase the likelihood of PML in natalizumab-treated patients can facilitate benefit–risk discussions between health care professionals and patients. Continued research and data collection will further develop our understanding of PML and the mechanisms by which these risk factors contribute to its development.

Publisher

SAGE Publications

Subject

Clinical Neurology,Neurology

Cited by 211 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3